Risperidone and Constipation Risk
Risperidone is generally NOT constipating and may actually be protective against constipation compared to other antipsychotics. In fact, among atypical antipsychotics, risperidone appears to have the least effect on gastrointestinal function and is associated with a reduced risk of severe constipation-related complications.
Evidence from FDA Drug Labeling
The FDA label data shows constipation rates with risperidone are comparable to or lower than placebo across multiple populations 1:
- Adult schizophrenia trials: Constipation occurred in <1% of risperidone-treated patients versus 0% with placebo
- Pediatric autism trials: Constipation rates were 10% with risperidone versus 12% with placebo 1
- Bipolar mania trials: Constipation was not listed among adverse reactions occurring in ≥2% of patients
This stands in stark contrast to other antipsychotics that are explicitly identified as constipating agents in clinical guidelines.
Clinical Research Findings
Recent pharmacovigilance data strongly supports risperidone's favorable gastrointestinal profile:
- A 2025 FDA Adverse Event Reporting System analysis found risperidone had an odds ratio of 0.71 for constipation - the only antipsychotic with a protective effect 2
- A 2025 multicenter study of 271 schizophrenia patients found risperidone users were significantly less likely to have functional constipation compared to users of quetiapine or aripiprazole 3
- A 2025 retrospective study of 4,114 hospitalized patients found high-dose risperidone was associated with reduced risk of severe constipation-related conditions (OR: 0.688) 4
Comparison to Other Antipsychotics
Clinical guidelines explicitly list phenothiazines and haloperidol as constipating agents 5. The research evidence shows:
- Highest constipation risk: Amisulpride (ROR 4.07), paliperidone (ROR 2.73), quetiapine (ROR 1.83), clozapine (ROR 1.61), olanzapine (ROR 1.50) 2
- Lowest risk: Risperidone (ROR 0.71) 2
Clinical Implications
When managing patients on antipsychotics:
- Risperidone can be considered a preferred option when constipation is a concern or pre-existing issue
- If a patient develops constipation on another antipsychotic, switching to risperidone may improve bowel function 3, 4
- Standard constipation prevention measures (adequate hydration >3000cc daily, dietary fiber, physical activity) remain important regardless of medication 3
- Monitor for anticholinergic burden from other medications, as these are the primary constipating culprits 5, 3
Important Caveat
While risperidone itself is not constipating, patients may still develop constipation from:
- Concurrent anticholinergic medications (antiparkinsonian agents, antidepressants)
- Other antipsychotics if on polypharmacy
- Underlying medical conditions
- Inadequate fluid intake or physical activity
The key distinction is that risperidone is not contributing to - and may actually mitigate - constipation risk compared to alternative antipsychotic options.